Heat shock protein-based vaccines and immunotherapies
AssigneeSloan-Kettering Institute for Cancer Research
InventorsJames E. Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.
Claims32
A composition for inducing an immune response to an infectious agent comprising:
- (a) a hybrid antigen comprising an antigenic domain of the infectious agent and a binding domain that non-covalently binds to an hsp70 and comprises a heptameric region having the sequence motif HyXHyXHyXHy (SEQ ID NO:29) where Hy represents a hydrophobic amino acid and X is any amino acid;
- and
- (b) an hsp70;
- wherein the binding domain and the antigenic domain are covalently bound in vitro;
- and
- wherein the hybrid antigen and the hsp70 are non-covalently bound.
A composition for inducing an immune response to an infectious agent, comprising:
- (a) a hybrid antigen comprising an antigenic domain of the infectious agent and a binding domain that comprises a peptide that non-covalently binds to an hsp70;
- and
- (b) an hsp70;
- wherein the binding domain and the antigenic domain are covalently bound in vitro;
- and
- wherein the hybrid antigen and the hsp70 are non-covalently bound.
A composition comprising an hsp70 and a hybrid antigen, the hybrid antigen consisting essentially of an antigenic domain of an infectious agent and a binding domain that non-covalently binds to an hsp70, wherein the antigenic domain is from a first source and the binding domain is from a second source different from the first source, and wherein the binding domain and the antigenic domain are covalently bound in vitro.
A composition comprising an hsp70 and a hybrid antigen, the hybrid antigen consisting essentially of an antigenic domain of an infectious agent, a binding domain that non-covalently binds to an hsp70, and a peptide linker separating the antigenic domain and the binding domain, wherein the antigenic domain is from a first source and the binding domain is from a second source different from the first source, and wherein the binding domain, the linker, and the antigenic domain are covalently bound in vitro.
Dependencies are inferred from the claim text.